Management of patients with newly diagnosed rheumatoid arthritis

Rheumatology

Volumn 38, Issue SUPPL. 2, 1999, Pages 27-31

  Emery, P ^a   Marzo, H ^a   Proudman, S ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

DMARDs; HRUS; LEAP; NSAIDs; PISA; Prognosis; Rheumatoid arthritis; Therapy; Toxicity; YEAR

Indexed keywords

ANTIRHEUMATIC AGENT; CORTICOSTEROID; CYCLOSPORIN A; HYDROXYCHLOROQUINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE;

CONFERENCE PAPER; DIAGNOSTIC IMAGING; DRUG CHOICE; HUMAN; JOINT INJURY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RHEUMATOID ARTHRITIS; SIDE EFFECT;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FORECASTING; HUMANS; PATIENT SELECTION; PROGNOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0032692182     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (26)

1. Wilske KR. Inverting the therapeutic pyramid: observations and recommendations on new directions in rheumatoid arthritis therapy based on the author's experience. Semin Arthritis Rheum 1993;23:11-8.
2. Fries JF, Williams CA, Ramey D, Bloch DA. The relative toxicity of disease-modifying antirheumatic drugs. Arthritis Rheum 1993;36:297-306.
3. Van Leeuwen MA, van Rijswijk MH, van der Heijde DM et al. The acute-phase response in relation to radiographic progression in early rheumatoid arthritis: a prospective study during the first three years of the disease. Br J Rheumatol 1993;32(suppl. 3):9-13.
4. Gough AK, Lilley J, Eyre S, Holder RL, Emery P. Generalised bone loss in patients with early rheumatoid arthritis. Lancet 1994;344:23-7.
5. Devlin J, Gough A, Huisson A et al. The acute phase and function in early rheumatoid arthritis. C-Reactive protein levels correlate with functional outcome. J Rheumatol 1997; 24:9-13.
6. Möttönen TT. Prediction of erosiveness and rate of development of new erosions in early rheumatoid arthritis. Ann Rheum Dis 1988;47:648-53.
7. Emery P. Rheumatoid arthritis: not yet curable with intensive therapy. Lancet 1997;350:304-5.
8. Emery P. The Dunlop-Dottridge lecture. Prognosis in inflammatory arthritis: the value of HLA genotyping and the oncological analogy. J Rheumatol 1997;24:1436-42.
9. Symmons DP, Jones MA, Scott DL, Prior P. Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol 1998; 25:1072-7.
10. van der Heide A, Jacobs JW, Bijlsma JW et al. The effectiveness of early treatment with 'second-line' antirheumatic drugs. A randomized, controlled trial. Ann Intern Med 1996;124:699-707.
11. Egsmose C, Lund B, Borg G et al. Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study. J Rheumatol 1995;22:2208-13.
12. Emery P. Therapeutic approaches for early rheumatoid arthritis: How early? How aggressive? Br J Rheumatol 1995;34(suppl. 2):87-90.
13. Emery P. The optimal management of early rheumatoid disease: the key to preventing disability. The Roche rheumatology prize lecture. Br J Rheumatol 1994;33:765-8.
14. Emery P. Selective COX-2 inhibition: clinical relevance in arthritis. Curr Opin Rheumatol 1996;8(suppl. 1):S21-4.
15. Tunn EJ, Bacon PA. Differentiating persistent from self-limiting symmetrical synovitis in an early arthritis clinic. Br J Rheumatol 1993;32:97-103.
16. Emery P, Symmons DP. What is early rheumatoid arthritis? Definition and diagnosis. Baillière's Clin Rheumatol 1997; 11:13-26.
17. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
18. Devlin J, Lilley J, Gough A et al. Clinical associations of dual-energy x-ray absorptiometry measurement of hand bone mass in rheumatoid arthritis. Br J Rheumatol 1996; 35:1256-62.
19. Emery P, Salmon M, Bradley H et al. Genetically determined factors as predictors of radiological change in patients with early symmetrical arthritis. Br Med J 1992;305:1387-9.
20. Gough A, Faint J, Salmon M et al. Genetic typing of patients with inflammatory arthritis at presentation can be used to predict outcome. Arthritis Rheum 1994; 37:1166-70.
21. O'Dell JR, Haire CE, Erikson N et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996;334:1287-91.
22. Haagsma CJ, van Riel PL, de Rooj DJ et al. Combination of methotrexate and sulphasalazine vs methotrexate alone: a randomized open clinical trial in rheumatoid patients resistant to sulphasalazine therapy. Br J Rheumatol 1994; 33;1049-55.
23. Tugwell P, Pincus T, Yocum D et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The methotrexane-cyclosporine combination study group. N Engl J Med 1995; 333:137-41.
24. Boers M, Verhoeven AC, Markusse HM et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18.
25. Proudman SP, Richardson C, Green MJ et al. Treatment of poor prognosis early RA: conventional therapy with sulphasalazine vs aggressive therapy with methotrexate, cyclosporin A and intra-articular corticosteroids. Arthritis Rheum 1997;40(suppl. 9):S92.
26. Rooney M, Whelan A, Fieghery C, Brenishan B. Changes in lymphocyte infiltration of the synovial membrane and the clinical course of rheumatoid arthritis. Arthritis Rheum 1989;32:361-9.